FUJIFILM Diosynth Biotechnologies Unveils New Facility in Holly Springs

Why It Matters:

The new facility represents a significant investment in biopharmaceutical manufacturing and will contribute to advancements in medicine. It will create job opportunities and boost the local economy, while also positioning the region as a hub for the life sciences industry.

The Details:

• The new FUJIFILM Diosynth Biotechnologies (FDB) facility in Holly Springs was unveiled, featuring seven buildings spread across nearly 1 million square feet.

• Janssen, a Johnson & Johnson company, will be the first tenant at the facility once it opens in 2025.

• The $2 billion facility will be the largest end-to-end CDMO biopharmaceutical manufacturing facility in North America.

• It will house state-of-the-art biopharmaceutical manufacturing equipment and technology, including two large-scale manufacturing suites.

• The facility will cover everything from drug substance manufacturing to packaging, assembly, and labeling.

• FDB's current site in Morrisville focuses on early-stage programs and smaller volumes, while the Holly Springs facility will handle medicine production at a larger scale.

• Roughly 725 jobs are expected to be created by the project by the end of 2028.

• FDB owns 150 acres of land in Holly Springs for the project, taking advantage of the region's trained workforce in the life sciences industry.

Conclusion:

The unveiling of the new FUJIFILM Diosynth Biotechnologies facility in Holly Springs marks a significant milestone in biopharmaceutical manufacturing. The state-of-the-art facility will attract companies and create job opportunities, contributing to the growth and development of the life sciences industry in the region.